Effect of Genetic Variation of IL-13 on Airway Remodeling in Bronchial Asthma  by Nagashima, Hiromi et al.
Allergology International Vol 60, No3, 2011 www.jsaweb.jp 291
Effect of Genetic Variation of IL-13 on
Airway Remodeling in Bronchial
Asthma
Hiromi Nagashima1, Yutaka Nakamura1, Hiroyuki Kanno2, Takashi Sawai2,
Hiroshi Inoue3 and Kohei Yamauchi1
ABSTRACT
Background: IL-13 is a major stimulator of inflammation and tissue remodeling at sites of Th2 inflammation,
and common single-nucleotide polymorphisms in IL13 are associated with allergic phenotypes in several ethni-
cally diverse populations. In particular, IL13Q110 is the non-conservative replacement of a positively charged
arginine (R) with a neutral glutamine (Q) at position 110 of IL-13, and as we already know, individuals homozy-
gous for glutamine (Q110Q110) are strongly associated with asthma and IgE. IL13Q110 has been demon-
strated to show that increased allergic inflammation depended on the enhanced IL-13-mediated Th2 effector
function. Therefore, we investigated whether Q110Q110 accelerated the decline in pulmonary function and
development of airway remodeling of asthmatic patients in the general population.
Methods: A total 336 asthmatic subjects living in Japan were recruited, genotyped, and had a pulmonary func-
tion test performed on them. To analyze airway inflammation and remodeling, bronchial lavage fluid (BLF) and
endobronchial biopsy specimens were examined.
Results: Forced expiratory volume in one second (FEV1), %predicted, forced expiratory volumeforced vital
capacity ratio, and forced expiratory flow 25-75%, % predicted were significantly decreased in Q110Q110
compared to R110R110, and the decline in FEV1 was increased significantly in Q110Q110 compared to R
110R110. The concentration of IL-13, IL-23, IL-11, GM-CSF, hyaluronic acid, and CCL8 in BLF were in-
creased in Q110Q110 compared to R110R110 and the thickness of the subepithelial layer was thicker.
Conclusions: Our study demonstrates that Q110Q110 increases, at least in part, allergic inflammation and
the propensity for airway remodeling, thus resulting in low lung function.
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INTRODUCTION
The histopathologic features of bronchial asthma are
associated with airway remodeling as consequences
of hypertrophyhyperplasia of the airway smooth
muscles and of subepithelial basement membrane
thickening.1 The latter response is most prominent in
the lamina reticularis2 and results from interstitial col-
lagen and proteoglycan deposition.3 The formation of
new blood vessels may also play an important role
both in the development of bronchial asthma and in
the physiologic repair process.4 Although initially de-
scribed in postmortem studies, these structural al-
terations can be observed even in mild and newly di-
agnosed cases of asthma.5,6 To date, many studies
have focused on the mechanisms underlying the
acute and presentation of bronchial asthma, and the
factors responsible for the more chronic structural
changes within the airway have been defined. IL-13 is
a pleiotropic 12-kDa product of a gene on chromo-
some 5 at q31 that is produced in large quantities by
stimulated Th2 cells. IL-13 contributes as the major
effector of Th2 inflammation and tissue remodeling.7
In accordance with these observations, IL-13 dysregu-
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lation has been documented, and IL-13 has been im-
plicated in the pathogenesis of a variety of diseases
characterized by inflammation and tissue remodeling,
including asthma, idiopathic pulmonary fibrosis,8 and
chronic obstructive pulmonary disease (COPD).9
Several genome-wide searches for quantitative traits
underlying IL-13 have been performed. For example,
IgE levels and allergic inflammation is associated
with IL13-1112C > T in some populations10 (functional
studies support a regulatory role for the -1111 variant,
which enhances IL13 promoter activity in CD4 posi-
tive lymphocytes11) and IL13-1512A > C in others.12
We have found a variant of the IL13 gene (rs20541),
in which arginine residue at amino acid 110 (R110) is
substituted with glutamine (Q110).13 This variant was
associated with bronchial asthma in both Japanese
and British populations. The variant showed a lower
affinity with the IL-13 receptor α2 chain (IL13Rα2),
which is a decoy receptor that antagonizes inflamma-
tory, remodeling, and physiologic responses, causing
less clearance.14 The variant also demonstrated an
enhanced stability in plasma level.14 These data lead
us to hypothesize that IL13 Q110 contributes to air-
way remodeling by driving inflammation and fibrosis
production. As the pulmonary function of Q110 ho-
mozygote in the asthmatic has not been established,
we first examined the airway limitation manifested by
a low force expiratory volume in 1s (FEV1) adjusting
for covariates, such as age, gender, height, atopy, and
a history of smoking of asthmatic patients, and per-
formed comparisons among Q110Q110, Q110R110,
and R110R110. Subsequent bronchial specimens’ ex-
aminations provided insights into the mechanisms of
airway remodeling of asthmatic patients with IL13
Q110 homozygote.
METHODS
STUDY SUBJECTS
All study subjects were recruited from the Iwate
Medical University Hospital. Patients with bronchial
asthma diagnosed according to the America Thoracic
Society (ATS) criteria, who had no other medical dis-
orders, and were not current smokers, were consid-
ered for the study, which was approved by Iwate
Medical University Hospital Ethics Committee. Pro-
spective patients were then notified of our desire to
include them in our study and asked if they would be
willing to participate. Upon acceptance, the subjects
were provided written informed consent according to
the ethical protocols of our institution. Subjects were
assessed for age, sex, duration of asthma, history of
smoking, spirometry, and eosinophils count. DNA
was isolated from lymphocytes using standard proce-
dures. Subjects were genotyped using (rs20541)
Q110Q110, Q110R110, and R110R110 (7500 Fast
Real-Time PCR System, Applied Biosystems, CA,
USA) to evaluate the relationship of pulmonary func-
tion with airway remodeling.
SPIROMETRY AND METHACHOLINE CHAL-
LENGE
To fulfill the ATS criteria for asthma, spirometry was
performed and airway methacholine responsiveness
was measured using an Astograph (Jupiter 21,
CHEST, Tokyo, Japan), according to the method de-
scribed by Takishima et al.15 The maximum FEV1 of
as many as 5 technically acceptable blows was re-
corded, both at baseline and at the end of the follow-
up, according to the ATS criteria for reproducibility.
ONE YEAR OF FOLLOW-UP AND COMPARISON
OF FEV1
In this study, the decline in FEV1 was calculated by
the differences between the results of baseline and
those of the following year. Patients recorded details
of asthma-related events, use of additional asthma
medications, asthma symptoms, restrictions in daily
activities, and sleep problems caused by asthma be-
tween scheduled hospital visits. Changes in concur-
rent medications, including inhaled or systemic corti-
costeroids, could be made if an investigator judged
this necessary to achieve asthma control. Serious ad-
verse events were collected from submitted reports
and by questioning at the hospital.
FIBREOPTIC BRONCHOSCOPY AND SPECIMEN
HANDLING
Bronchial lavage fluid (BLF) and bronchial biopsy
were performed by inserting a flexible fibreoptic
bronchoscope (Olympus; Olympus Optical Co., Ltd.,
Tokyo, Japan) under local anesthesia, as described
elsewhere in detail.16 BLF was always done before
the biopsy to prevent blood contamination. The BLF
was carried out in one of the subsegmental bronchi of
the left lingular division by the injection of two 20 ml
aliquots of sterile phosphate-buffered saline (PBS)
pre-warmed to 36.5℃ and gently aspirated back into
polypropylene tubes kept on ice. We obtained 20-25
ml of BLF from all subjects. Immediately after lavage,
mucus was removed from the fluid by filtration
through gauze, and fluid was then centrifuged at 200x
g for 10 min at 4℃. The supernatant was decanted
and stored at -80℃. The cell pellet was washed in
PBS and a total cell count was performed using a dis-
posable cell counting chamber (Cellometer, Nexce-
lom Bioscience LLC, MA, USA). The cells were then
diluted with PBS to a concentration of 1 × 106ml. Cy-
tocentrifuge slides were prepared and stained with a
May-Grünwald-Giemsa, and a differential cell count
was done in 300 cells. BLF cells were used for im-
munocytochemistry and the supernatant of BLF was
stored at -80℃ until use. Five biopsies were taken us-
ing forceps (Olympus; Olympus Optical Co., Ltd.) in
the segmental bronchi of the right lobe and the bifur-
cations of right bronchi. Biopsied specimens were
fixed in 4% paraformaldehyde and immersed in su-
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crose, thereafter embedded in OCT compound. Five
micrometer tissue sections were affixed to micro-
scope slides and readied for histology. Hematoxylin
and eosin (HE) staining was then carried out. The
thickness of the subepithelial layer was measured on
the biopsies stained by HE. All stained sections were
coded and examined in a blinded manner at the end
of the study. All available sections for each patient
were evaluated. Biopsies were considered suitable for
examination when there was at least 1.0 mm of
subepithelial layer length with an intact epithelium.
At least 3 suitable biopsy sections were examined per
subject. The thickening of the subepithelial layer in
individual biopsy specimens were measured in mi-
crometers (μm), making measurements at 20 μm in-
tervals along the whole length of the membrane,
while taking only the adequately preserved and ori-
ented area into account. There were then analyzed
using the Olympus DP70 system (Olympus) and
computer image analysis (Image-Pro Pus 4.1; Media
Cybernetics, MD, USA). The intra-observer error was
assessed by performing three separate counts of the
same section on different occasions and was calcu-
lated to be less than 5%.
PRELIMINARY STUDY USING MICROARRAY
ANALYSIS
Microarray analysis was carried out to estimate what
biomarkers increased in BLF from those homozy-
gous for Q110 compared to those homozygous for
R110.
CO-CULTURE OF STIMULATED AND IL-13-
EXPRESSED PBMCs WITH FIBROBLASTS
Antibodies were immobilized on 6-well tissue culture
plates by incubating 20 μgml anti-CD3 (R&D Sys-
tems, Inc., MN, USA) and 10 μgml anti-CD28 (R&D
Systems, Inc.) in PBS overnight at 4℃. Excess anti-
bodies were removed by washing the wells with PBS.
PBMCs were randomly obtained from three asthma
patients with Q110Q110 and three asthma patients
with wild type (wt) R110R110. Heparinised venous
blood was centrifuged on Histopaque 1077 (Sigma,
Tokyo, Japan) at 600 g for 20 min at room tempera-
ture. The detailed protocol of PBMCs isolation has
been reported elsewhere.17 PBMCs were plated at
the bottom of the 6-well tissue culture plates to be
stimulated by CD3 and CD28 at a density of 1 × 106
cellswell. Co-culture experiments were performed in
6-well plate ThinCert Cell Culture Inserts Systems
(Greiner Bio-One, Frickenhausen, Germany). Human
lung fibroblasts were purchased (Takara BIO Inc.,
Shiga, Japan) and maintained in fibroblast basal me-
dium (FBM; Takara BIO Inc.) supplemented with
10% fetal calf serum. Fibroblasts (1 × 105) were
seeded onto the inserts and incubated at 37℃ with 5%
CO2 in the air until they were 80% confluent, and
thereafter inserts with fibroblasts were put into the 6-
well tissue culture plates of CD3 and CD28- stimu-
lated PBMCs’ and incubated in FBM for 18 h. Fibro-
blasts, which were stimulated by IL-13 Q110Q110 or
IL-13 R110R110 produced by PBMCs, were submit-
ted to microarray analysis.
MICROARRAY
The fibroblasts’ mRNA expressions were assessed by
co-culture with or without stimulated PBMCs ob-
tained from Q110Q110 and R110R110 individuals.
RNA was extracted from cultured fibroblast by an
miRNA Isolation Kit (Applied Biosystems) according
to the procedure provided by the vender.
cRNA PREPARATION
A 500 ng of aliquot of total RNA was reverse tran-
scribed into cDNA using the Quick Amp Linear Am-
plification Kit (Agilent Technologies, CA, USA). The
synthesized cDNA was transcribed into cRNA and la-
belled with either cyanine 3-labelled nucleotide (Ag-
ilent Technologies). Labelled cRNA was purified with
RNeasy Mini columns (Qiagen, CA, USA). The qual-
ity of each cRNA sample was verified by total yield
and specificity calculated based on a NanoDrop ND-
1000 spectrophotometer measurement (NanoDrop
Technologies, DE, USA).
MICROARRAY HYBRIDIZATION
Labelled cRNAs with a specificity greater than 8 were
used for hybridization using the in situ hybridization
kit plus (Agilent Technologies). Arrays were incu-
bated at 65℃ for 17 h in Agilent’s microarray hybridi-
zation chambers. After hybridization, arrays were
washed according to the protocol (Agilent Technolo-
gies).
IMAGE PROCESSING
Slides were scanned immediately after washing on
the Agilent DNA Microarray Scanner (G2505C) us-
ing the one color scan setting for 4 × 44 k array slides
(Scan Area 61 × 21.6 mm, scan resolution of 5 μm,
dye channel is set to Green and Green PMT is set to
100%).
The scanned images were analyzed with Feature
Extraction Software 10.5.1.1 (Agilent Technologies)
using the default parameters (protocol GE1-v5_10_
Apr08 and Grid: 014850_D_F_20080627) to obtain
background subtracted and spatially detrended Proc-
essed Signal intensities.
NORMALIZATION AND STATISTICAL ANALYSIS
The microarray data were analyzed by using Agilent
Genespring GX 11. The signal intensity of each gene
was firstly normalized with the total intensity of all
genes from the microarray, and then the normalized
signal of each treatment was compared with the
mock-treatment to determine the relative fold
changes of gene expression. The threshold level for
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Table　1　Subject demographic characteristics
Domain/IL-13 genotype R110/R110(n = 127)
Q110/R110
(n = 154)
Q110/Q110
(n = 55)
Statistical results
MANOVA,
ANOVA, or χ2
Age, yr 42.7 (15.3) 49.3 (18.9) 45.1 (12.7) NS
Sex, n (%) 63 men (51) 71 men (46) 26 men (59) NS
Pack-years of smoking 5.2 (2.2) 4.1 (1.8) 5.5 (2.1) NS
Eosinophil count, μl-1 248.7 (73) 211.0 (98) 263.0 (102) NS
Pulmonary function test MANOVA < 0.01
FEV1, %predicted 98.4 (23.1) 92.7 (20.5) 65.3 (12.3) 0.03
FEV1/FVC 76.2 (14.9) 75.0 (11.0) 62.2 (15.9) 0.04
FEF25-75%, %predicted 73.0 (20.3) 59.1 (21.2) 35.7 (18) 0.03
Decline in FEV1 (ml/yr) 27.0 (3.1) 29.0 (2.2) 33.4 (11.9) 0.04
Data are presented as mean ± (standard deviation). NS = Not signifi cant (p > 0.05). p values are for analyses of variance (ANOVA) un-
less otherwise specifi ed. Multivariate analyses of variance (MANOVA) were performed to analyze the predictive factors for the impairment 
of lung function test parameters and were used as dependent variables, while age, sex, and tobacco were used as covariates.
ANOVA results reported only within outcome domains with signifi cant MANOVA result.
Post hoc comparisons reported only for variables with signifi cant ANOVA result.
FEV1, forced expiratory volume in one second; FEV, forced expiratory volume; FVC, forced vital capacity; FEF25-75%, forced expiratory
fl ow 25-75%.
up- or down-regulation of gene expression was the
level of changes2-fold.
CYTOKINE CONCENTRATION OF BLF SUPER-
NATANT
Various cytokines concentrations in BLF supernatant
were analyzed when there were significant differ-
ences in the mRNA level of fibroblasts in the co-
culture system between Q110Q110 and R110R110.
SAMPLE SIZE
The BLF and biopsy study sample size was calculated
based on the results of previous studies, assessing
the concentration of cytokines and hyaluronic acid,
and the thickening of the subepithelial layer of asth-
matic patients. However, other studies have exam-
ined the concentration of mediators using condensed
bronchoalveolar lavage fluid obtained from the pa-
tients with bronchial asthma, which is a method dif-
ferent from our procedures. Subepithelial layer thick-
ness was measured by Vignola et al.18 and our group2
previously, and was not mentioned nor classified in
the genetic variant of IL13 homozygous for Q110 and
R110. Vignola et al. reported a 11 μm subepithelial
layer thickness within severe asthmatic patients, and
we reported a 8.1 μm subepithelial layer thickness
with mild asthmatic patients. Therefore, the expected
difference between mild and severe asthma patients’
subepithelial layer thickness was 2.9 μm. Results
from these studies indicated that 16 patients had to
be included to show a significant difference (alpha =
0.05, power = 80%). Accounting for a maximum of a
10% dropout rate and for 80% of patients potentially
non-compliant with bronchoscopic examination from
our previous experiments,4,16,19-21 a minimum of 160
patients had to be recruited.
STATISTICAL ANALYSIS
All data are expressed as the mean ± SD. Multivariate
analyses of variance (MANOVA) were performed to
analyze the predictive factors for the impairment of
lung function parameters. In this model, pulmonary
function test parameters (%FEV1, FEVFVC, %FEF
25-75%, and decline in FEV1) were used as dependent
variables, while age, sex, history of tobacco use, and
the group of subjects served as covariates. Compari-
sons of pulmonary function and thickening of subepi-
thelial layer among the three groups were performed
using the one-way ANOVA. JMP version 8.0.2 (SAS
Institute Japan, Tokyo, Japan) was the software used
for statistical analysis.
RESULTS
CHARACTERISTICS OF STUDY POPULATION
The characteristics of patients are presented in Table
1. There were 336 asthmatic patients in the study
group. R110 homozygote occupied 38%, heterozygote
occupied 46%, and Q110 homozygote occupied 16% of
the total recruited asthmatic patients. There were no
differences in age, sex, history of smoking, or eosino-
phils count status among the three groups, however,
FEV1, FEV1FVC, %FEF25-75%, and a decline in FEV
1year were significant differences among three
groups. There are significant decreases of %FEV1,
FEV1FVC, and %FEF25-75% in Q110Q110 com-
pared to R110R110 (Table 1). There is also a signifi-
cant increase of decline in FEV1 in Q110Q110 com-
pared to R110R110 (Table 1). No patients in either
group discontinued participation during the 1-year
follow-up.
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Table　2　Summary of lL-13 Q110/Q110-regulated genes 
identifi ed by microarray analysis
Gene name Gene accessionnumber
Expression
ratio
IL23A NM_016584 93.336
IL11 NM_000641 32.284
CR618615 CR618615 29.078
IL24 NM_006850 28.190
THC2640944 THC2640944 27.431
CSF2 NM_000758 18.526
HAS1 NM_001523 17.756
PTGS2 NM_000963 15.075
CSF3 NM_000759 13.536
FLJ33590 NM_173821 12.448
RHCG NM_016321 12.315
CCL8 NM_005623  9.130
C15orf48 NM_032413  7.711
ENST00000303979 ENST00000303979  5.677
A_24_P928031 A_24_P928031  4.131
EFFECTS OF GENETIC VARIANT OF IL-13 ON FI-
BROBLAST GENE EXPRESSION PROFILES AS
MEASUREDWITH THE cDNA MICROARRAY
The lower pulmonary function that was found in asth-
matic patients with a genetic variant of IL13Q110
Q110 suggested that the airway strongly responded
to this cytokine, and then proceeded to fibrosis. To
test this idea, we seeded PBMCs derived from three
of each of the Q110Q110 or R110R110 patients with
asthma onto the well to detect their interaction with
fibroblasts, which were seeded onto inserts. Some of
the mRNA expression of fibroblasts by co- cultivation
with PBMCs were increased when the PBMCs were
obtained from Q110Q110 patients with asthma. The
summarized results for important genes are shown in
Table 2. These data were the average of each of the
three patients. IL-23A mRNA expression increased in
response to CD3 and CD28-stimulated PBMCs de-
rived from asthmatic patients with Q110 compared to
R110 (93.336-fold). The mRNA expression of IL-11,
IL-24, CSF2GM-CSF, HAS1, PTGS2, CSF3G-CSF,
CCL8MCP-2 were also increased compared to R110.
DETECTION OF IL-13, IL-23, IL-11, GM-CSF,
HYALURONIC ACID, AND CCL8 IN BLF
To confirm whether Q110Q110 individuals ex-
pressed increased protein levels, which were indi-
cated in the microarray data, we performed a bron-
choscopy and collected BLF from the three groups,
R110R110, Q110R110, and Q110Q110. Sixteen
asthmatic patients with Q110Q110, fifteen patients
with Q110R110, and eighteen patients with R110
R110 were accepted for the BLF and bronchial biopsy
study. A chi-square test was used to compare all the
gene assessed patients and the bronchoscope treated
patients in pulmonary function, but we found no dif-
ferences between the two groups. Bronchoscopic ex-
amination with BLF collection was performed with
safety and was well tolerated in all subjects. All indi-
cated data above were determined by a commercially
available ELISA test. IL-13 levels in BLF were as-
sessed by the SRL laboratories (Tokyo, Japan). Be-
cause of the different sensitivities of Q110 and R110
to this assay, the values of Q110 and R110 obtained
by the kit were adjusted to the basis of known pro-
teins as a standard. IL-13, IL-23, IL-11, CSF-2GM-
CSF, hyaluronic acid, and CCL8MCP-2 are signifi-
cantly increased in Q110Q110 compared to R110
R110 individuals (Table 3), while no significant differ-
ence was found for G-CSF and IL-24 between asth-
matic patients with Q110Q110 and R110R110 (data
not shown).
THICKNESS OF SUBEPITHELIAL LAYER
Subsequently, we investigated the differences of
thickness in the subepithelial layer of the bronchial
mucosa (Table 3). The subepithelial layer was signifi-
cantly thicker in the biopsies taken from the asth-
matic subjects with Q110Q110 compared to R110
R110 individuals (Table 3, Fig. 1). Thus, airway re-
modeling in Q110Q110 had increased progression
compared to that in R110R110 subjects.
DISCUSSION
Several new findings have emanated from this study.
First, we have demonstrated asthmatic patients with
genetic variants of IL-13Q110Q110 are significantly
associated with a reduced pulmonary function, as
manifested by a low %FEV1, FEV1FVC, %FEF25-
75%, and a decline in FEV1 adjusting for covariates,
such as age, sex, and history of smoking in Japanese
patients. Secondly, an increased mRNA level of IL-23
A, IL-11, IL-24, CSF2GM-CSF, HAS-1, PTGS2,
CSF3G-CSF, and CCL8MCP-2 in cultured fibro-
blasts were observed initially, and the protein level of
IL-13, IL-23, IL-11, GM-CSF, hyaluronic acid, and
CCL8MCP-2 in BLF were shown. Finally, we have
observed that the subepithelial layer was significantly
thicker in the biopsy samples taken from the patients
with Q110Q110 compared to R110R110 individuals.
A Q110 polymorphism in exon 4 has been shown to
be associated with high total serum IgE levels,22,23
atopic dermatitis,22 and asthma13 in German,22,23
American,23 British,13 and Japanese13 populations. In
functional assays, Vladich et al.24 have shown that IL-
13 Q110 significantly increased signal transducer and
activator of transcription-6 phosphorylation and CD23
expression in primary human monocytes compared
to IL-13R110. Arima et al.14 have demonstrated that
the affinity of Q110 and R110 to IL-13Rα1 was almost
equal, whereas Q110 showed a slightly lower affinity
with IL13Rα2, a decoy receptor, than with R110, and
Nagashima H et al.
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Fig.　1　Bronchial biopsies were obtained from asthmatic patients. Representative photomicrographs 
show bronchial mucosal biopsy specimens stained with hematoxylin and eosin (× 400, HE staining).
a) Asthmatic subject of IL13R110/R110. b) IL13Q110/R110. c) IL13Q110/Q110.
a b c
Table　3　Clinical characteristics of bronchoscopic study population
Domain/IL-13 genotype R110/R110(n = 16)
Q110/R110
(n = 15)
Q110/Q110
(n = 18)
Statistical 
results ANOVA
Pulmonary function test
FEV1, %predicted 94.3 (22.1) 90.7 (15.3) 66.4 (10.2) 0.02
FEV/FVC 78.2 (13.3) 77.2 (10.3) 64.0 (14.4) 0.02
FEF 25-75%, %predicted 71.8 (16.2) 62.0 (18.5) 33.8 (15.8) 0.01
Decline in FEV1 (ml/yr) 25.4 (2.6) 27.8 (3.0) 32.1 (11.3) 0.04
BLF concentration of mediators
IL-13 9.8 (1.7) 11.5 (10.0) 19.3 (13.9) 0.02
IL-23 12.1 (5.6) 10.6 (3.3) 25.0 (11.4) 0.01
IL-11 8.7 (8.2) 11.1 (7.7) 22.6 (13.0) 0.02
GM-CSF 24.0 (7.4) 18.4 (14.3) 35.2 (12.6) 0.02
Hyaluronic acid 66.3 (5l.5) 76.1 (69.2) 178.6 (102.9) 0.01
CCL8 11.4 (5.9) 18.0 (7.6) 24.6 (14.2) 0.02
Subepithelial layer thickness 6.4 (3.3) 8.7 (4.6) 11.6 (2.7) 0.04
Data are presented as mean ± (standard deviation). p values are for analyses of variance (ANOVA).
Post hoc comparisons reported only for variables with signifi cant ANOVA result.
FEV1, forced expiratory volume in one second; FEV, forced expiratory volume; FVC, forced vital capacity; FEF25-75%, forced expiratory
fl ow 25-75%.
then that Q110 enhanced stability in vitro and in vivo
compared to R110. Thus inflammation is amplified by
the local responses of the epithelium, smooth muscle,
fibroblasts, and macrophages through the IL13Q110
stability. In the present study, we demonstrated the
increased IL-13, IL-23, IL-11, CSF-2GM-CSF,
hyaluronic acid, and CCL8MCP-2 in BLF from IL13
Q110 homozygote, all of which are known to play es-
sential roles in allergic inflammation and the genera-
tion of IL-13-induced airway remodeling. Previous
studies showed the importance of IL-23 in the devel-
opment of allergic airway inflammation.25 IL-11
mRNA positive cells have previously been shown to
have inverse correlations with the FEV1 values for
the asthmatic patients.26 Moreover, IL-13 transgenic
mice studies have shown in full detail that IL-13 in-
duced IL-11, IL-11 receptor α, hyaluronic acid, and
MCP-2CCL8 are found in their lungs.27 Woolley
et al.28 have shown that allergen inhalation caused a
significant increase in eosinophils and GM-CSF in
bronchoalveolar lavage fluid in patients of asthma.
Thus, IL-13 dominated-tissue inflammation was pre-
ceded to the airway remodeling in asthmatic patients.
Since a polymorphic variant of Q110Q110 has been
found with a minor allele frequency of approximately
20% in the Caucasian population,23 it is likely that
asthmatic patients with IL13Q110 were enrolled in
pairs matched for pulmonary function regardless of
being homozygous for Q110. The START study,
which enrolled 7241 patients aged 5 to 66 years with
recent-onset, mild persistent asthma to assess early
intervention with the inhaled corticosteroid budeson-
ide on long-term asthma control, demonstrated that
early intervention with ICSs did not affect lung func-
tion.29 The CAMP study treated children from 5 to 12
years of age with low-dose inhaled budesonide, nedo-
cromil, or placebo for at least 4 years. The results
from the CAMP study also did not demonstrate any
difference in the postbrochodilator FEV1 between
treatments.30 These clinical asthmatic studies, which
are inherently elusive, lead us to speculate that pa-
tients with IL-13Q110 population might influence
Genetic Variation IL-13 and Remodeling
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FEV1 against efficacy of ICS or nedocromil treat-
ments.
In conclusion, we have demonstrated an important
role for IL-13Q110 in airway remodeling using pulmo-
nary function test and bronchial specimens. Addi-
tional investigations of therapeutic utility aimed at
regulating IL-13Q110 in IL-13-and Th2-mediated mi-
lieu are warranted.
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